New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
Ikena Oncology (IKNA) Acquires Pionyr Immunotherapeutics in All-Stock Transaction
-
Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction
-
Bright Health Group Secures Financing to Support Operations Pending the Expected Close of California Medicare Advantage Business Sale
-
Insurtech Startup Functional Finance Raises $8 Million to Further Expand Operational Efficiency for the Insurance Industry
-
Nexo Therapeutics Launches With $60 Million Series A Financing
-
Form 4 Sagimet Biosciences Inc. For: Jul 18 Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
TEDCO Announces FY24 Board of Directors
-
Gossamer Bio Inc. (GOSS) Announces $212M Private Placement Financing
-
Gossamer Bio Announces $212 Million Private Placement Financing
-
Savara (SVRA) Prices 21M Share Offering at $3/sh
-
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
NEA Welcomes Mark Hawkins as Venture Partner
-
First U.S. Patients Implanted with Innovative FIRE1 Remote Heart Failure Monitoring System in Early Feasibility Study
-
MBX Biosciences Appoints Steven J. Prestrelski, Ph.D., M.B.A., as Chief Scientific Officer
-
Form SC 13D/A MINERVA SURGICAL INC Filed by: NEW ENTERPRISE ASSOCIATES 13 LP
-
Aigen Unveils the World's First AI-Driven, Solar-Powered, Agricultural Robotics Service
-
Mirati Therapeutics (MRTX) Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
-
Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director
-
Form SC 13D/A Mirum Pharmaceuticals, Filed by: New Enterprise Associates 16, L.P.
-
Form SC 13D/A Arcellx, Inc. Filed by: New Enterprise Associates 15, L.P.
-
AvoMD Raises $5M to Combat Clinician Burnout With No-Code Clinical App Building Platform
-
Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics
-
Form 4 Mirum Pharmaceuticals, For: Jun 13 Filed by: New Enterprise Associates 16, L.P.
-
Kyber Knight Capital Launches With a $120 Million Inaugural Fund
-
DJUST Raises €12M to Simplify B2B Commerce Across Europe, UK and US
-
Form SC 13D/A IonQ, Inc. Filed by: New Enterprise Associates 15, L.P.
-
Granica Launches Industry-first AI Efficiency Platform to Cut Cloud Data Costs up to 80% and Boost ROI from AI Initiatives
-
Instabase Doubles Valuation to $2B and Launches AI Hub, A Generative AI Based Platform for Content Understanding
-
Pionyr Immunotherapeutics’ Phase 1a Study of TREM1-targeting Antibody PY159 for the Treatment of Solid Tumors Featured at ASCO 2023
-
Kira Learning Raises $15M Series A to Fuel National Expansion of its Platform to Empower K-12 Teachers and Students to Teach and Learn Computer Science
-
MBX Biosciences to Participate in Jefferies Healthcare Conference
-
Timescale Announces Corporate Rebrand Reflecting Company's Growth
-
Union.ai announces $19.1M Series A and launches all-new Union Cloud to simplify AI and data workflows for all
-
NEA Appoints Technology Investors Aaron Jacobson and Vanessa Larco to Senior Investing Team Roles; Lily Huang, Danielle Lay and Luke Pappas Promoted to Partner
-
X4 Pharmaceuticals (XFOR) Announces $65 Million Private Placement of Common Stock, Warrants
-
X4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-Market
-
BluWave-Ai Expands EV Everywhere Commercial Adoption With Smartcar's Vehicle APIs
-
Regulus Therapeutics Reports First Quarter 2023 Financial Results and Recent Updates
-
Orby AI Emerges from Stealth, Announces Funding to Build Generative AI Software That Learns What You Do and Does It For You
-
MBX Biosciences to Participate in May Investor Conferences
-
Minerva Surgical Reports First Quarter 2023 Financial Results
-
Concerned Shareholders of Cano Health (CANO) Issue Open Letter Regarding the Board’s Entrenchment Maneuvers and Latest Governance Failures
-
Concerned Shareholders of Cano Health Issue Open Letter Regarding the Board’s Entrenchment Maneuvers and Latest Governance Failures
-
Stablix and Vertex Establish Strategic Collaboration to Discover and Develop Targeted Protein Stabilization Therapeutics
-
Kindred, Members-Only Home Swapping Network, Announces 5,000 Nights Swapped and Series A Funding to Revolutionize the Sharing Economy
-
Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain
-
HEAVY.AI Launches HEAVY 7.0, Introducing Real-Time Machine Learning Capabilities
-
Relievant Medsystems Raises $50 Million to Advance the Treatment for Chronic Vertebrogenic Low Back Pain
-
Regulus Therapeutics (RGLS) Announces $15M Private Placement
-
Regulus Therapeutics Announces $15 Million Private Placement of Equity

